

## KEY FIGURES ON BIOSIMILAR MEDICINES



**Nearly 7 billion**  
**patient treatment days**

with EU approved  
biosimilar medicines  
since 2006



The number of treatment  
days with anti-TNF medicines  
**increased x2**  
from 2013-2023



**€56 billion**  
**cumulative savings**  
from the impact of biosimilar  
competition since 2006,  
**€6 billion**  
in 2024 alone



A growing opportunity  
for patients with over  
**110 new biologic**  
**medicines** opening to  
biosimilar competition  
by 2032



A considerable  
opportunity for European  
healthcare budget: a

**€53.5Bn**  
market will **open to**  
**competition** by 2032



By 2030,  
**1st cell & gene**  
**therapies** will open to  
biosimilar competition



**Biosimilar candidates** are  
under development for  
**1/3 of biologics**  
losing exclusivity by 2032



Biosimilar medicines  
represent **4%** of the  
**total pharmaceutical**  
**spending** in Europe (<€10  
billion)

**Nearly 7 billion**  
**patient treatment days**  
with EU approved  
biosimilar medicines since  
2006



Thanks to biosimilar  
competition, **the number  
of treatment days** with  
anti- TNF medicines  
increased **x2**  
from 2013-2023



**€56 billion**  
**cumulative savings**  
from the impact of biosimilar  
competition since 2006,  
**€6 billion**  
in 2024 alone



A growing opportunity  
for patients with over  
**110 new biologic  
medicines** opening  
to biosimilar  
competition by 2032




A considerable opportunity  
for European healthcare  
budget: a **€53.5Bn**  
market will **open to**  
**competition** by 2032



By 2030,  
**1st cell & gene**  
**therapies** will open to  
biosimilar competition



Biosimilar medicines  
opportunity remains largely  
untapped with only  
**12% volume share**  
of the accessible market in  
Europe





Biosimilar medicines  
represent **4%** of the  
**total pharmaceutical  
spending** in Europe  
(<€10 billion)



**Biosimilar candidates**  
are under development for  
**1/3 of biologics**  
losing exclusivity by 2032

